First of all, what IS cancer?
Cancer describes a group of diseases in which cells rapidly divide, grow out of control, and can spread to other areas in the body. Cancer development is spurred by changes in genes, called mutations, that lead to uncontrolled cell growth and other types of cellular dysfunction.
DNA Mutations
A mutation is a change.
During cell division (mitosis), the DNA within a cell is replicated, transcribed (written), and translated to make DNA for new daughter cells. This is a complicated, multi-step operation in which a lot of mistakes can be made. When a mistake occurs during DNA replication, it is called a mutation. Mutations can also "pre-exist" in the body if they were inherited from a parent's genes, or they can occur as the result of exposure to carcinogens (cancer-causing substances).
Fortunately, we have a built-in system of checks and balances to limit, prevent, and repair mutations, but mistakes can also occur within that system. When a mutation is not corrected, two things happen: 1) any resulting problems from that mutation can develop in the body (e.g. cells grow uncontrollably) and 2) the mutation is passed down to the next generation of daughter cells and the problems persist. ((A mutation is like a bug stuck on the screen of a photocopying machine. Once it's there, all of the copies moving forward will contain that "bug."))
Chris Gunter, PhD, Associate Investigator at the National Human Genome Research Institute notes, "Did you know that on any average day, the 37 trillion cells in your body will acquire trillions of point mutations? These changes come from random errors in copying DNA as the cell divides or from environmental exposures, like cigarette smoke or even sunshine. It sounds a little scary, but almost all of these changes are in parts of your genome where it does not really matter. Your cells have also evolved ways to deal with some point mutations and correct them back to your original genome. But the very rare point mutation in your somatic cells, which are the cells that won't be sperm or eggs, ultimately could lead to symptomatic disease."
A mutation can impact activities at the cellular level: it can turn genes on, off, up, or down (expression, regression, overexpression, or loss of expression) which can then lead to under- or overproduction of proteins or the production of proteins that don't function properly. Some mutations may cause a lot of problems and other mutations may cause no issue at all. When these mutations impact genes that protect us from cancer, like tumor suppressor genes that control out-of-control cell growth or DNA repair genes, then we have a problem.
If we think of DNA as a blueprint for a house then a mutation would be a minor change to that blueprint. While that change might appear to be minor, it could be quite problematic. Let's say the original blueprint called for a solid wall to be built alongside the primary shower, but a change occurred that is now directing the general contractor to install electrical outlets along the same wall. We now have a fire hazard and an electrocution hazard where there should have been a simple wall. Small change. Big impact.
Is cancer smart?
Its IQ is certainly not what we're referring to here, but cancer cells are incredibly plastic, adaptive, and heterogenous. Cancer cells "taste" their environment, and then use that information to benefit their survival. If they taste something they don't like, they can ignore it, work around it, etc. And when they taste something they like, they can capitalize, gobble it up, and use it to their benefit. An example of this would be a tumor creating a perfect tumor microenvironment (TME) around themselves that not only provides everything the cancer cells need to grow and proliferate, but the TME also forms a protective "capsule" that is challenging for immune cells to penetrate. Think about how we, as people, adapt to different climates, for example. Over time, we learn what to do, not to do, how to dress, how to hydrate and eat, limitations of outdoor activities, etc. Cancer does the same thing. If it's cold, it'll grab a coat so it can stay and thrive without having to relocate.
Why is it so hard to treat and cure cancer?
Isn't it all the same, just in different places in the body?
It's not all the same.
Heterogeneity, or a state of having differences, exists between cancer types, within cancer types, between tumors within the same body, and even between subpopulations of cells within a single tumor. There's a lot of variation within cancer, and each variation presents unique challenges with regard to therapy response and patient outcomes.
Furthermore, the differences that exist between and within tumors are not static—tumors can, and often do, change over time. Scientists and oncologists not only have to differentiate between all these variations and how treatment and prognosis are impacted, they also have to try to keep up as the tumors evolve over the course of treatment and (observation.)
It's a moving target.
“Treating cancer as one disease is like treating Africa as one country. Even in the same patient, it is not the same disease at two sites or at two different points in time. Vicious and self-obsessed, it learns to grow faster and become stronger, smarter, and more dangerous with each successive division.” -Azra Raza, MD in The First Cell
Heterogenous Tumors
If you were to examine a tumor specimen under a microscope, you would likely not find a cluster of identical cells. Most tumors are made up of a variety of cells with varying genomes, functions, and susceptibilities. The cells in the center of the tumor may be very distinct from those on the surface of the tumor, and that variance applies to all of the cells between the surface and the core. Given the heterogeneity of tumors, it's challenging to develop a unified treatment approach, even within the same cancer type or within the same person's body.
Why does heterogeneity matter in cancer?
What can cause cancer to change over time?
There is much more in store for this page so please stay tuned! In the meantime, you can visit the resources section below to learn more about cancer biology.
If you haven't already, please check out our Newly Diagnosed page for a thorough overview of the early cancer experience.
We regularly review these resources to make sure that all links work correctly and are of value to our visitors. If you find a link that isn't working, please email coral@oncologyoffense.com. If you would like us to consider adding a resource to our list, please email us with details.
What is Cancer? (NCI)
Cell Biology of Cancer (NCI)
https://training.seer.cancer.gov/disease/cancer/biology/
The Hallmarks of Cancer (Hanahan, D. and Weinberg, RA. Cell, Vol 100, 57-70, January 7, 2000)
Hallmarks of cancer: the next generation. (Hanahan D , Weinberg RA . Cell 2011;144:646–74.)
Hallmarks of Cancer: New Dimensions (Hanahan, Douglas Cancer Discov (2022) 12 (1): 31–46.)
Molecular Biology and Evolution of Cancer: From Discovery to Action (Somarelli et al. Molecular Biology and Evolution, Volume 37, Issue 2, February 2020, Pages 320–326) https://doi.org/10.1093/molbev/msz242
Tumor heterogeneity and cancer cell plasticity (Meacham, Corbin E, and Sean J Morrison. “Tumour heterogeneity and cancer cell plasticity.” Nature vol. 501,7467 (2013): 328-37. doi:10.1038/nature12624)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521623/
Tumour heterogeneity and resistance to cancer therapies (Dagogo-Jack, I., Shaw, A. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15, 81–94 (2018). https://doi.org/10.1038/nrclinonc.2017.166)
https://www.nature.com/articles/nrclinonc.2017.166
Tumor heterogeneity: preclinical models, emerging technologies, and future applications (Proietta, M. Et al., Front. Oncol., 27 April 2023 Sec. Molecular and Cellular Oncology Volume 13 -2023)
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1164535/full
Targeting the tumor microenvironment: Potential strategy for cancer therapeutics (Babar, et al. BBA- Molecular Basis of Disease Volume 1869, Issue 6, August 2023)
Cancer Cells v. Normal Cells: How Are They Different? (Verywell Health, 2023)
https://www.verywellhealth.com/cancer-cells-vs-normal-cells-2248794
Targeting cancer stem cell pathways for cancer therapy (Yang, et al. Sig Transduct Target Ther 5, 8, 2020) Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been considered promising therapeutic targets for cancer therapy. These cells have self-renewal capacity and differentiation potential and contribute to multiple tumor malignancies, such as recurrence, metastasis, heterogeneity, multidrug resistance, and radiation resistance.
https://www.nature.com/articles/s41392-020-0110-5
Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies (Walcher, et al. Front Immunol. 2020; 11: 1280. Published online 2020 Aug 7) The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest over the last decades. In particular, the analysis of biomarkers in cancer patients within the pre- and post-therapeutic period is required to identify several types of cells, which carry a risk for a disease progression and subsequent post-therapeutic relapse. Cancer stem cells (CSCs) are a subpopulation of tumor cells that can drive tumor initiation and can cause relapses.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426526/
Understanding the Immune System (antigens, antibodies, etc.) (Society for Immunotherapy of Cancer)
What is Epigenetics, and Why Is Everyone Talking About It? (MSKCC, 2018)
https://www.mskcc.org/news/what-epigenetics-and-why-everyone-talking-about-it
Genetics vs. Genomics Fact Sheet (NIH- National Human Genome Research Institute) Genetics and genomics both play roles in health and disease. Genetics refers to the study of genes and the way that certain traits or conditions are passed down from one generation to another. Genomics describes the study of all of a person's genes (the genome).
The Human Protein Atlas is a Swedish-based program initiated in 2003 with the aim to map all the human proteins in cells, tissues, and organs using an integration of various omics technologies, including antibody-based imaging, mass spectrometry-based proteomics, transcriptomics, and systems biology. All the data in the knowledge resource is open access to allow scientists both in academia and industry to freely access the data for exploration of the human proteome.
Copyright © 2024 Oncology Offense - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.